logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5662.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5662.produseast1
Showing 1 - 20 of 40 Items
Showing 1 - 20 of 40 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Ali MH,  et al.
2025-07-16 • Lancet Respiratory Medicine
2025-07-16 • Lancet Respiratory Medicine
Journal Article
|
Editorial
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Protocol
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Commentary
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Letter
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Protocol
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research

Feasibility of using tuberculin skin test screening for initiation of 36-month isoniazid preventive therapy in HIV-infected patients in resource-constrained settings

Huerga H, Vasquez B, Mekiedje C, 

Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy

Kuksa L, Andrejak C, Haecker B, Bothamley G, Calcagno A,  et al.
2025-03-01 • IJTLD OPEN
2025-03-01 • IJTLD OPEN

Pretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approve...

Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A,  et al.
2025-01-29 • New England Journal of Medicine
2025-01-29 • New England Journal of Medicine

BACKGROUND

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...

Nine-month, all-oral regimens for rifampin-resistant tuberculosis

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Abubakirov A,  et al.
2024-01-29 • medRxiv
2024-01-29 • medRxiv

BACKGROUND

Aft...

Management of rifampicin-resistant tuberculosis in conflict-affected areas: The case of Iraq

Tesfahun HM, Al-Salihi L, Abdulkareem Al-Ani N, Mankhi AA, Mohammed A,  et al.
2024-01-19 • PLOS One
2024-01-19 • PLOS One
Since December 2019, the World Health Organization (WHO) has encouraged National Tuberculosis Programs to deprioritize the use of injectable-containing regimens and roll-out all-oral bed...

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M,  et al.
2023-11-30 • Trials
2023-11-30 • Trials
BACKGROUND
Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yi...

Operationalising targeted next-generation sequencing for routine diagnosis of drug-resistant TB

Iyer AS, Ndlovu Z, Sharma J, Mansoor H, Bharati M,  et al.
2023-06-21 • Public Health Action
2023-06-21 • Public Health Action
BACKGROUND
Phenotypic drug susceptibility testing (pDST) for Mycobacterium tuberculosis can take up to 8 weeks, while conventional molecular tests identify a limited set of resistanc...

Diagnostic yield of urine lipoarabinomannan and sputum tuberculosis tests in people living with HIV: a systematic review and meta-analysis of individual participant data

Broger T, Koeppel L, Huerga H, Miller P, Gupta-Wright A,  et al.
2023-06-01 • Lancet Global Health
2023-06-01 • Lancet Global Health
BACKGROUND
Sputum is the most widely used sample to diagnose active tuberculosis, but many people living with HIV are unable to produce sputum. Urine, in contrast, is readily availab...

Caring for adolescents and young adults with tuberculosis or at risk of tuberculosis: Consensus statement from an international expert panel

Chiang SS, Waterous PM, Atieno VF, Bernays S, Bondarenko Y,  et al.
2023-03-01 • Journal of Adolescent Health
2023-03-01 • Journal of Adolescent Health

Clinical utility of target-based next-generation sequencing for drug-resistant TB

Mansoor H, Hirani N, Chavan VV, Das M, Sharma J,  et al.
2023-01-01 • International Journal of Tuberculosis and Lung Disease
2023-01-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
In high TB burden countries, access to drug susceptibility testing is a major bottleneck. Targeted next-generation sequencing (tNGS) is a promising technology for rapid re...

Novel FujiLAM assay to detect tuberculosis in HIV-positive ambulatory patients in four African countries: a diagnostic accuracy study

Huerga H, Bastard M, Lubega AV, Akinyi M, Antabak NT,  et al.
2023-01-01 • Lancet Global Health
2023-01-01 • Lancet Global Health
BACKGROUND
Development of rapid biomarker-based tests that can diagnose tuberculosis using non-sputum samples is a priority for tuberculosis control. We aimed to compare the diagnost...

Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India

Dhakulkar S, Das M, Sutar N, Oswal V, Shah D,  et al.
2021-02-18 • PLOS One
2021-02-18 • PLOS One
BACKGROUND
Childhood and adolescent drug-resistant TB (DR-TB) is one of the neglected infectious diseases. Limited evidence exists around programmatic outcomes of children and adoles...

Introduction of new drugs for drug-resistant TB in Iraq

Tesfahun HM, Moussally K, Al-Ani NA, Al-Salhi LG, Kyi HA,  et al.
2021-12-01 • International Journal of Tuberculosis and Lung Disease
2021-12-01 • International Journal of Tuberculosis and Lung Disease

TB screening, prevention and treatment cascade in a Malawi prison

Mangochi P, Bossard C, Catacutan C, Van Laeken D, Kwitonda C,  et al.
2022-10-01 • International Journal of Tuberculosis and Lung Disease
2022-10-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
Incarcerated individuals, especially in high HIV and TB burden settings, are at increased risk of latent TB infection and/or TB disease. We implemented a comprehensive HIV...

Psychiatric comorbidities among patients with complex drug-resistant tuberculosis in Mumbai, India

Laxmeshwar C, Das M, Mathur T, Israni T, Jha S,  et al.
2022-02-11 • PLOS One
2022-02-11 • PLOS One
BACKGROUND
People with drug-resistant tuberculosis (DR-TB) are known to suffer from many mental-health disorders. This study aims to describe the proportion of patients diagnosed wit...

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial

Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E,  et al.
2021-09-25 • Trials
2021-09-25 • Trials
BACKGROUND
Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. W...

Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study

Ferlazzo G, Mohr E, Laxmeshwar C, Hewison CCH, Hughes J,  et al.
2018-02-13 • Lancet Infectious Diseases
2018-02-13 • Lancet Infectious Diseases
BACKGROUND
Bedaquiline and delamanid have been approved for treatment of multidrug-resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns, patients ...

Ambulatory management of pre- and extensively drug resistant tuberculosis patients with imipenem delivered through port-a-cath: A mixed methods study on treatment outcomes and challenges

Chavan VV, Dalal A, Nagaraja SB, Thekkur P, Mansoor H,  et al.
2020-06-16 • PLOS One
2020-06-16 • PLOS One
Background
Imipenem, an intravenous antibiotic is recommended for use in drug resistant tuberculosis (DR-TB) when an effective regimen with combination of other second line drugs is...

Challenging drug-resistant TB treatment journey for children, adolescents and their care-givers: A qualitative study

Das M, Mathur T, Ravi S, Meneguim A, Iyer AS,  et al.
2021-03-10 • PLOS One
2021-03-10 • PLOS One
Background: Childhood multidrug-resistant TB (MDR-TB) still affects around 25000 children every year across the globe. Though the treatment success rates for drug-resistant TB (DR-TB) in...
Mueller YK, 
Ferlazzo G, 
et al.
2015-11-11 • Journal of Acquired Immune Deficiency Syndromes (1999)
2015-11-11 • Journal of Acquired Immune Deficiency Syndromes (1999)